摘要
目的调查12岁以下儿童腺病毒(adenovirus,Ad)感染所诱发的免疫力状况,尤其是针对5.型腺病毒(Ad5)的免疫力状况,旨在筛选应用Ad5重组疫苗和基因治疗剂的适宜人群。方法通过采集华东部分省市和地区12岁以下儿童的血清标本,采用ELISA方法检测Ad非特异性总抗体(Ad Total antibody,Ad-TAb),用蚀斑减少中和试验(Plague Reduction Neutralization Test,PRNT)来检测Ad5中和抗体(Ad5 neutralizing antibody,Ad5-NAb),用Stata9.0软件进行数据分析。结果经过ELISA和PRNT检测,发现Ad-TAb和Ad5-NAb的滴度水平以及各组标本的阳性率,均随着年龄的增长而呈上升的趋势。以低于2岁的年龄组各项数据最低,与其它各组有显著性差异(P〈0.05).结论在12岁以下儿童人群中,以低于2岁的年龄组应用Ad5型重组疫苗或基因治疗剂是可行的。
Objective To investigate the adenovirus (Ad) infection-induced immunity in the children who are below 12 years old, especially for the immunity against adenovirus serotype 5 (Ad5). Methods Serum samples were collected from children under the age of 12 in the eastern regions of China, and screened by using ELISA for total antibodies of adenovirus (Ad-Tab), and Ad5 neutralizing antibodies (Ad5-NAb) were determined by using the plaque reduction neutralization test (PRNT). Stata 9.0 software was used for data analysis. Results After ELISA and PRNT assay, the titer levels of Ad-TAb and AdS-NAb, and positive rates of each group of specimens are increased with ages. The data of below 2-year-old age group is the lowest among these four groups after statistical analysis. Conclusions In this study, we observed that younger than 2-year-old age is suitable for application of Ad5-based recombinant vaccine or gene therapeutic agents.
出处
《公共卫生与临床医学》
2010年第3期187-190,共4页
Public health and dinical medicine
基金
山东省教育厅科技计划项目(J07YE06)
山东省医药卫生科技发展计划项目(2007HW134)